secwatch.observer — SEC 8-K summary
======================================

Issuer:     HALOZYME THERAPEUTICS, INC. (HALO)
CIK:        0001159036
Form:       8-K
Filed at:   2025-10-03T23:59:59+00:00
Accession:  0001193125-25-230348
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Halozyme to acquire Elektrofi for $750M upfront plus up to $150M in milestones
------------------------------------------------------------------------------

- Halozyme will pay $750M cash upfront for Elektrofi, subject to customary adjustments for debt, cash, expenses, and net working capital.
- Up to three $50M milestone payments conditional on separate product regulatory approvals.
- Reverse termination fee of $36M payable by Halozyme if agreement terminated under certain circumstances.
- Transaction expected to close within 12 months, subject to HSR and other customary closing conditions.
- Certain employee options assumed and converted into Halozyme options, reducing cash consideration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1159036/000119312525230348/0001193125-25-230348-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1159036/000119312525230348/d807496d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-230348

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer